Anti-C1q antibodies in systemic lupus erythematosus

A-M Orbai; L Truedsson; G Sturfelt; O Nived; H Fang; G S Alarcón; C Gordon; Jt Merrill; P R Fortin; I N Bruce; D A Isenberg; D J Wallace; R Ramsey-Goldman; S-C Bae; J G Hanly; J Sanchez-Guerrero; A E Clarke; C B Aranow; S Manzi; M B Urowitz; D D Gladman; K C Kalunian; M I Costner; V P Werth; A Zoma; S Bernatsky; G Ruiz-Irastorza; M A Khamashta; Søren Jacobsen; J P Buyon; P Maddison; M A Dooley; R F Van Vollenhoven; E Ginzler; T Stoll; C Peschken; J L Jorizzo; J P Callen; S S Lim; B J Fessler; M Inanc; D L Kamen; A Rahman; K Steinsson; A G Franks; L Sigler; S Hameed; N Pham; R Brey; M H Weisman; G McGwin; L S Magder; M Petri

doi:10.1177/0961203314547791

Anti-C1q antibodies in systemic lupus erythematosus

A-M Orbai, L Truedsson, G Sturfelt, O Nived, H Fang, G S Alarcón, C Gordon, Jt Merrill, P R Fortin, I N Bruce, D A Isenberg, D J Wallace, R Ramsey-Goldman, S-C Bae, J G Hanly, J Sanchez-Guerrero, A E Clarke, C B Aranow, S Manzi, M B UrowitzD D Gladman, K C Kalunian, M I Costner, V P Werth, A Zoma, S Bernatsky, G Ruiz-Irastorza, M A Khamashta, Søren Jacobsen, J P Buyon, P Maddison, M A Dooley, R F Van Vollenhoven, E Ginzler, T Stoll, C Peschken, J L Jorizzo, J P Callen, S S Lim, B J Fessler, M Inanc, D L Kamen, A Rahman, K Steinsson, A G Franks, L Sigler, S Hameed, N Pham, R Brey, M H Weisman, G McGwin, L S Magder, M Petri

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

101 Citationer (Scopus)

Abstract

OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.

METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.

RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).

CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

Originalsprog	Engelsk
Tidsskrift	Lupus
Vol/bind	24
Udgave nummer	1
Sider (fra-til)	42-49
Antal sider	8
ISSN	0961-2033
DOI	https://doi.org/10.1177/0961203314547791
Status	Udgivet - jan. 2015

Adgang til dokumentet

10.1177/0961203314547791

Citationsformater

Orbai, A-M., Truedsson, L., Sturfelt, G., Nived, O., Fang, H., Alarcón, G. S., Gordon, C., Merrill, J., Fortin, P. R., Bruce, I. N., Isenberg, D. A., Wallace, D. J., Ramsey-Goldman, R., Bae, S-C., Hanly, J. G., Sanchez-Guerrero, J., Clarke, A. E., Aranow, C. B., Manzi, S., ... Petri, M. (2015). Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 24(1), 42-49. https://doi.org/10.1177/0961203314547791

Anti-C1q antibodies in systemic lupus erythematosus. / Orbai, A-M; Truedsson, L; Sturfelt, G; Nived, O; Fang, H; Alarcón, G S; Gordon, C; Merrill, Jt; Fortin, P R; Bruce, I N; Isenberg, D A; Wallace, D J; Ramsey-Goldman, R; Bae, S-C; Hanly, J G; Sanchez-Guerrero, J; Clarke, A E; Aranow, C B; Manzi, S; Urowitz, M B; Gladman, D D; Kalunian, K C; Costner, M I; Werth, V P; Zoma, A; Bernatsky, S; Ruiz-Irastorza, G; Khamashta, M A; Jacobsen, Søren; Buyon, J P; Maddison, P; Dooley, M A; Van Vollenhoven, R F; Ginzler, E; Stoll, T; Peschken, C; Jorizzo, J L; Callen, J P; Lim, S S; Fessler, B J; Inanc, M; Kamen, D L; Rahman, A; Steinsson, K; Franks, A G; Sigler, L; Hameed, S; Pham, N; Brey, R; Weisman, M H; McGwin, G; Magder, L S; Petri, M.

I: Lupus, Bind 24, Nr. 1, 01.2015, s. 42-49.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, GS, Gordon, C, Merrill, J, Fortin, PR, Bruce, IN, Isenberg, DA, Wallace, DJ, Ramsey-Goldman, R, Bae, S-C, Hanly, JG, Sanchez-Guerrero, J, Clarke, AE, Aranow, CB, Manzi, S, Urowitz, MB, Gladman, DD, Kalunian, KC, Costner, MI, Werth, VP, Zoma, A, Bernatsky, S, Ruiz-Irastorza, G, Khamashta, MA, Jacobsen, S, Buyon, JP, Maddison, P, Dooley, MA, Van Vollenhoven, RF, Ginzler, E, Stoll, T, Peschken, C, Jorizzo, JL, Callen, JP, Lim, SS, Fessler, BJ, Inanc, M, Kamen, DL, Rahman, A, Steinsson, K, Franks, AG, Sigler, L, Hameed, S, Pham, N, Brey, R, Weisman, MH, McGwin, G, Magder, LS & Petri, M 2015, 'Anti-C1q antibodies in systemic lupus erythematosus', Lupus, bind 24, nr. 1, s. 42-49. https://doi.org/10.1177/0961203314547791

Orbai, A-M ; Truedsson, L ; Sturfelt, G ; Nived, O ; Fang, H ; Alarcón, G S ; Gordon, C ; Merrill, Jt ; Fortin, P R ; Bruce, I N ; Isenberg, D A ; Wallace, D J ; Ramsey-Goldman, R ; Bae, S-C ; Hanly, J G ; Sanchez-Guerrero, J ; Clarke, A E ; Aranow, C B ; Manzi, S ; Urowitz, M B ; Gladman, D D ; Kalunian, K C ; Costner, M I ; Werth, V P ; Zoma, A ; Bernatsky, S ; Ruiz-Irastorza, G ; Khamashta, M A ; Jacobsen, Søren ; Buyon, J P ; Maddison, P ; Dooley, M A ; Van Vollenhoven, R F ; Ginzler, E ; Stoll, T ; Peschken, C ; Jorizzo, J L ; Callen, J P ; Lim, S S ; Fessler, B J ; Inanc, M ; Kamen, D L ; Rahman, A ; Steinsson, K ; Franks, A G ; Sigler, L ; Hameed, S ; Pham, N ; Brey, R ; Weisman, M H ; McGwin, G ; Magder, L S ; Petri, M. / Anti-C1q antibodies in systemic lupus erythematosus. I: Lupus. 2015 ; Bind 24, Nr. 1. s. 42-49.

@article{45e3d554ff06422da57252aaafd2c1c5,

title = "Anti-C1q antibodies in systemic lupus erythematosus",

abstract = "OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.",

author = "A-M Orbai and L Truedsson and G Sturfelt and O Nived and H Fang and Alarc{\'o}n, {G S} and C Gordon and Jt Merrill and Fortin, {P R} and Bruce, {I N} and Isenberg, {D A} and Wallace, {D J} and R Ramsey-Goldman and S-C Bae and Hanly, {J G} and J Sanchez-Guerrero and Clarke, {A E} and Aranow, {C B} and S Manzi and Urowitz, {M B} and Gladman, {D D} and Kalunian, {K C} and Costner, {M I} and Werth, {V P} and A Zoma and S Bernatsky and G Ruiz-Irastorza and Khamashta, {M A} and S{\o}ren Jacobsen and Buyon, {J P} and P Maddison and Dooley, {M A} and {Van Vollenhoven}, {R F} and E Ginzler and T Stoll and C Peschken and Jorizzo, {J L} and Callen, {J P} and Lim, {S S} and Fessler, {B J} and M Inanc and Kamen, {D L} and A Rahman and K Steinsson and Franks, {A G} and L Sigler and S Hameed and N Pham and R Brey and Weisman, {M H} and G McGwin and Magder, {L S} and M Petri",

note = "{\textcopyright} The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.",

year = "2015",

month = jan,

doi = "10.1177/0961203314547791",

language = "English",

volume = "24",

pages = "42--49",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications",

number = "1",

}

TY - JOUR

T1 - Anti-C1q antibodies in systemic lupus erythematosus

AU - Orbai, A-M

AU - Truedsson, L

AU - Sturfelt, G

AU - Nived, O

AU - Fang, H

AU - Alarcón, G S

AU - Gordon, C

AU - Merrill, Jt

AU - Fortin, P R

AU - Bruce, I N

AU - Isenberg, D A

AU - Wallace, D J

AU - Ramsey-Goldman, R

AU - Bae, S-C

AU - Hanly, J G

AU - Sanchez-Guerrero, J

AU - Clarke, A E

AU - Aranow, C B

AU - Manzi, S

AU - Urowitz, M B

AU - Gladman, D D

AU - Kalunian, K C

AU - Costner, M I

AU - Werth, V P

AU - Zoma, A

AU - Bernatsky, S

AU - Ruiz-Irastorza, G

AU - Khamashta, M A

AU - Jacobsen, Søren

AU - Buyon, J P

AU - Maddison, P

AU - Dooley, M A

AU - Van Vollenhoven, R F

AU - Ginzler, E

AU - Stoll, T

AU - Peschken, C

AU - Jorizzo, J L

AU - Callen, J P

AU - Lim, S S

AU - Fessler, B J

AU - Inanc, M

AU - Kamen, D L

AU - Rahman, A

AU - Steinsson, K

AU - Franks, A G

AU - Sigler, L

AU - Hameed, S

AU - Pham, N

AU - Brey, R

AU - Weisman, M H

AU - McGwin, G

AU - Magder, L S

AU - Petri, M

PY - 2015/1

Y1 - 2015/1

N2 - OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

AB - OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

U2 - 10.1177/0961203314547791

DO - 10.1177/0961203314547791

M3 - Journal article

C2 - 25124676

VL - 24

SP - 42

EP - 49

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 1

ER -